Pain reduction and tolerability of mirogabalin in trigeminal neuralgia: A prospective observational study
Headache: The Journal of Head and Face Pain · 2026-11 · 66 (10) · 2371-2379
DOI: 10.1111/head.70134 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Headache: The Journal of Head and Face Pain, online erschienen am 25.06.2026. Verfasst von Hiroaki Matsumoto und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, Cerebrovascular Research Institute, Yoshida Hospital, Kobe, Japan. Hauptthemen laut MEDLINE: Trigeminal Neuralgia, Analgesics, Bridged Bicyclo Compounds. Die Arbeit nennt 32 Literaturangaben.
Abstract (Originalsprache)
Objectives/Background Our objective was to assess the short‐term treatment response and tolerability of mirogabalin in patients with trigeminal neuralgia. Trigeminal neuralgia is a debilitating neuropathic pain disorder for which carbamazepine is the first‐line therapy; however, this treatment is often limited by adverse effects. Mirogabalin, the third and most recently developed gabapentinoid, has demonstrated analgesic benefit with an acceptable safety profile in peripheral neuropathic pain conditions; however, its clinical role in trigeminal neuralgia remains unclear.
Methods
We conducted a prospective, open‐label, single‐arm observational pilot study at a single tertiary referral center in Japan between July 2021 and May 2025, enrolling 21 patients with trigeminal neuralgia, with pre‐ and postassessment of pain outcomes over a 3‐month follow‐up period. Pain intensity was assessed using the Numerical Rating Scale at baseline and at 1 and 3 months after treatment initiation. Responder rates and adverse events were also evaluated.
Results
The median Numerical Rating Scale score decreased from 6 (interquartile range [IQR], 6–8) at baseline to 2 (IQR, 2–4) at 1 month and 1 (IQR, 0–2) at 3 months (Friedman test, p < 0.001). At 1 month, 20 out of 21 patients (95%) achieved a ≥2‐point reduction, and all evaluable patients (20 out of 20) met this threshold at 3 months. Response rates for ≥70% improvement increased from 6 out of 21 (29%) at 1 month to 14 out of 20 (70%) at 3 months (McNemar test, p = 0.008). No patients discontinued treatment because of adverse events.
Conclusion
In this prospective, single‐arm pilot study, mirogabalin was associated with short‐term reductions in pain intensity and appeared to be generally well tolerated in patients with trigeminal neuralgia. These findings are hypothesis‐generating and require confirmation in larger, controlled, and longer‐term randomized trials to test the efficacy and safety of mirogabalin.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurosurgery, Cerebrovascular Research Institute, Yoshida Hospital, Kobe, Japan.
ORCID-Profile: Hiroaki Matsumoto, Akihiro Okada
Zitieren
APA
Matsumoto, H., Yoshida, Y., Okada, A., Tomogane, Y., Masuda, A., Yamaura, I., Minami, H., & Yoshida, Y. (2026). Pain reduction and tolerability of mirogabalin in trigeminal neuralgia: A prospective observational study. Headache: The Journal of Head and Face Pain, 66(10), 2371-2379. https://doi.org/10.1111/head.70134
Vancouver
Matsumoto H, Yoshida Y, Okada A, Tomogane Y, Masuda A, Yamaura I, et al. Pain reduction and tolerability of mirogabalin in trigeminal neuralgia: A prospective observational study. Headache: The Journal of Head and Face Pain. 2026;66(10):2371-2379. doi:10.1111/head.70134
BibTeX
@article{Matsumoto2026,
author = {Matsumoto, Hiroaki and Yoshida, Yasunori and Okada, Akihiro and Tomogane, Yusuke and Masuda, Atsushi and Yamaura, Ikuya and Minami, Hiroaki and Yoshida, Yasuhisa},
title = {Pain reduction and tolerability of mirogabalin in trigeminal neuralgia: A prospective observational study},
journal = {Headache: The Journal of Head and Face Pain},
year = {2026},
volume = {66},
number = {10},
pages = {2371--2379},
doi = {10.1111/head.70134}
}
EUVIMED